|Videos|November 26, 2013
Episode 2 - Immunotherapy in CRPC
Advertisement
Episodes in this series
During this segment, David Crawford, MD, discusses immunotherapy’s role in castration-resistant prostate cancer (CRPC), and explains how the US Food and Drug Administration’s approval of sipuleucel-T has led to a paradigm shift in the way that CRPC is treated.
Dr Crawford explains the unique capabilities of immunotherapy for advanced disease when compared to conventional treatment options such as cytotoxic chemotherapy.
Additionally, David Quinn, MD, discusses hormonal therapy agents, the key clinical trials that have tested these treatment options, and explains how the trials have demonstrated improved outcomes in CRPC.
Advertisement
Related to this article
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5